Shares of Regulus Therapeutics Inc (NASDAQ:RGLS) saw strong trading volume on Friday . 326,500 shares changed hands during mid-day trading, a decline of 62% from the previous session’s volume of 863,167 shares.The stock last traded at $1.18 and had previously closed at $1.20.
Several research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Tuesday, October 10th. Leerink Swann assumed coverage on shares of Regulus Therapeutics in a report on Friday. They set an “outperform” rating and a $2.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday, December 11th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and four have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $2.46.
The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77. The firm has a market cap of $128.90, a price-to-earnings ratio of -0.93 and a beta of 1.55.
WARNING: This piece of content was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3127648/regulus-therapeutics-rgls-sees-unusually-high-trading-volume.html.
About Regulus Therapeutics
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.